Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Joins Liver-Focused Biotech Launch with US$100 Million Partnership
August 10, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment Enters Japan PIII Study
August 10, 2018
- Mogamulizumab Bags US Approval for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
August 10, 2018
- As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
- Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
- Teijin Making Inroads into Biosimilar Arena with Sales Tie-Up for Enbrel Follow-On
August 9, 2018
- Kyorin Holdings President Pledges to Hit Midterm Management Targets; Desalex Performs Better-Than-Expected
August 9, 2018
- Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
- Maviret Remains Japan’s Best-Selling Drug in April-June: IQVIA
August 8, 2018
- Ethical Drug Sales Down 4.6% in June: Crecon
August 8, 2018
- Drug Wholesalers Log Sluggish Price Settlement Rates as They Run Careful Negotiations under New Guidelines
August 7, 2018
- Japan Lifestyle-Related Disease Treatment Market to Subside, after Peaking in 2018: Fuji Keizai
August 7, 2018
- AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
- Takeda, Whiz Partners to Set Up Joint Investment Fund to Spur Drug Ecosystem
August 6, 2018
- Amgen Astellas Seeks OK for Repatha Monotherapy Use in Statin-Intolerant Patients
August 6, 2018
- Rituxan Filed for Add’l Indication of Chronic Lymphocytic Leukemia
August 6, 2018
- Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
- AstraZeneca’s Japan Crestor Sales Dive 71%
August 3, 2018
- Ninlaro Production Site Opens in Russia: Takeda
August 3, 2018
- Thrombocytopenia Drug Mulpleta Earns FDA Approval: Shionogi
August 3, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…